White House is told the big three PBMs are ‘everything wrong with this industry’; Missing data is making it difficult for the pharmaceutical industry to help LGBTQ+ people

Taking stock of the drug industry, from the lab to the medicine chest

March 4, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | White House is told the big three PBMs are 'everything wrong with this industry' A trade group for pharmacy benefit managers complained a White House "listening session" was a "biased and unproductive discussion." By Ed Silverman Opinion: Missing data is making it difficult for the pharmaceutical industry to help LGBTQ+ people The pharma indusry has seen promising efforts in diversifying clinical trials. That work must also include LGBTQ+ populations. By Paul Shay STAT+ | Longer treatment gave better liver outcomes for MASH patients, Akero drug study shows Patients treated longer with the drug, efruxifermin, saw sustained reductions in the liver scarring that characterizes MASH. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser